Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
5.5200
+0.4200 (8.24%)
NASDAQ · Last Trade: Oct 2nd, 5:53 PM EDT
Detailed Quote
Previous Close
5.100
Open
5.210
Bid
5.500
Ask
5.510
Day's Range
5.115 - 5.610
52 Week Range
3.790 - 12.36
Volume
58,000,635
Market Cap
929.71M
PE Ratio (TTM)
-3.033
EPS (TTM)
-1.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
27,644,810
Chart
About Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)
Recursion Pharmaceuticals Inc is a biotechnology company focused on leveraging advanced computational biology and machine learning techniques to transform drug discovery and development. By utilizing a proprietary platform that integrates high-throughput biology and data science, the company aims to identify new therapeutic targets and accelerate the process of discovering novel medicines for a variety of diseases. Their innovative approach seeks to uncover hidden connections in biological data, enabling them to explore previously uncharted areas in the pharmaceutical landscape and bring forth breakthrough treatments for patients in need. Read More
A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human cells. This innovation, spearheaded by bioengineers at the University of California San Diego, promises to fundamentally transform our understanding of complex diseases
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This transformative shift is redefining traditional workflows, demanding a radical re-evaluation of skill sets, and igniting critical discussions around ethics, regulation, and the very
From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.
As the trading week draws to a close on Friday, September 26, 2025, Jim Cramer, the influential host of CNBC's "Mad Money," has once again offered his discerning insights into the stock market's immediate landscape. His top ten things to watch highlight a stark and growing bifurcation in the U.
On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Dutch Bros (NYSE: BROS). He recommended buying some now and then buying some of the stock in the $40s.
The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving market demands. New drug developments, particularly in sophisticated biologics, groundbreaking gene therapies, and blockbuster obesity treatments, are fundamentally altering therapeutic paradigms. Simultaneously, the pervasive integration of
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery for biotechnology companies. This strategic move aims to level the playing field, granting smaller biotechs access to sophisticated AI models trained on decades
Nvidia's six-stock portfolio of publicly traded AI stocks was worth $4.3 billion at the end of the second quarter, and the company also owns stakes in many privately held AI start-ups.
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Salt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
